SHBC1240

X.Q.KOH¹, H.H.OON¹, W.S.CHONG¹, X.ZHAO¹, E.S.T.TAN¹

National Skin Centre¹

This is the first interval analysis of the National Skin Centre Psoriasis Biologics Registry (SINGPSOR) since its establishment in 2017. The aims are to better understand the clinical characteristics and treatment outcomes in our local cohort of psoriasis patients receiving biologic therapies and/or conventional systemic therapies.

Data related to the demographics, clinical characteristics, treatments, adverse events, physician-rated and patient-reported outcome measures of patients enrolled between 14 August 2017 and 1 May 2021 were extracted from the registry and analysed. Patients on conventional systemic therapies were used as a comparator.

92 patients were enrolled; 58 had ≥2 visits (19 receiving conventional, 39 receiving biologic treatment). Patients receiving biologics were older, with longer duration of psoriasis (48 versus 34 years, 21 versus 6 years respectively, p<0.05). They were more likely to have prior conventional systemic therapy before enrolment (p<0.05). There were no significant baseline differences in BSA (body surface area), PASI (Psoriasis Area & Severity Index), DLQI (Dermatology Life Quality Index), PGA (Physician Global Assessment) and Itch scores between the groups. Ustekinumab was the only treatment with sufficient patients (N=19) having ≥2 visits for efficacy analysis. This subset demonstrated significant improvement in BSA and PASI by the first review.

Subsequent comparative evaluations of treatment efficacies in this cohort should consider that baseline differences suggest patients recruited to the biologic group could have psoriasis that was harder to manage. Future analyses of SINGPSOR, with larger sample size and longer follow-up, will be invaluable to further characterize these patients and their treatment outcomes.